X4 Pharma FY2022 net loss $93.9M; WHIM trial success, NDA submission planned for H2 2023

X4 Pharmaceuticals, Inc

Cash $123M as of Dec 31, 2022; funds operations into Q2 2024.
Phase 3 4WHIM trial met primary and key secondary endpoints; NDA submission expected early 2H 2023.
Phase 2 chronic neutropenia trial enrolling; data and regulatory path clarity expected 2Q/3Q 2023.
Gross proceeds ~$120M from two 2022 financings; amended Hercules loan lowered cash covenant to $20M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

X4 Pharmaceuticals, Inc reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 21, 2023, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other business highlights for the fourth quarter and full year ended December 31, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-23-008677

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.